Multiple-clone activation of hypnozoites is the leading cause of relapse in Plasmodium vivax infection

PLoS One. 2012;7(11):e49871. doi: 10.1371/journal.pone.0049871. Epub 2012 Nov 21.

Abstract

Background: Plasmodium vivax infection is characterized by a dormant hepatic stage, the hypnozoite that is activated at varying periods of time after clearance of the primary acute blood-stage, resulting in relapse. Differentiation between treatment failure and new infections requires characterization of initial infections, relapses, and clone multiplicity in vivax malaria infections.

Methodology/principal findings: Parasite DNA obtained from primary/relapse paired blood samples of 30 patients with P. vivax infection in Brazil was analyzed using 10 molecular markers (8 microsatellites and MSP-1 blocks 2 and 10). Cloning of PCR products and genotyping was used to identify low-frequency clones of parasites. We demonstrated a high frequency of multiple-clone infections in both primary and relapse infections. Few alleles were identified per locus, but the combination of these alleles produced many haplotypes. Consequently, the majority of parasites involved in relapse showed haplotypes that were distinct from those of primary infections. Plasmodium vivax relapse was characterized by temporal variations in the predominant parasite clones.

Conclusions/significance: The high rate of low frequency alleles observed in both primary and relapse infections, along with temporal variation in the predominant alleles, might be the source of reported heterologous hypnozoite activation. Our findings complicate the concept of heterologous activation, suggesting the involvement of undetermined mechanisms based on host or environmental factors in the simultaneous activation of multiple clones of hypnozoites.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alleles
  • Antimalarials / administration & dosage
  • Brazil
  • Chronic Disease
  • Female
  • Gene Frequency
  • Genotype
  • Haplotypes
  • Host-Parasite Interactions* / genetics
  • Host-Parasite Interactions* / immunology
  • Humans
  • Malaria, Vivax* / blood
  • Malaria, Vivax* / drug therapy
  • Malaria, Vivax* / genetics
  • Malaria, Vivax* / parasitology
  • Male
  • Merozoite Surface Protein 1 / genetics
  • Microsatellite Repeats / genetics
  • Middle Aged
  • Plasmodium vivax* / genetics
  • Plasmodium vivax* / metabolism
  • Plasmodium vivax* / pathogenicity
  • Recurrence
  • Treatment Failure
  • Young Adult

Substances

  • Antimalarials
  • Merozoite Surface Protein 1

Grants and funding

This work was supported by the Pronex malaria network: CNPq/Ministry of Health-DECIT; FAPEMAT; and FAPEMIG. CAB, LHC and CJF were supported by CNPq fellowships. FFA and AMR are supported by scholarships from CNPq and Fapemig, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.